• Title/Summary/Keyword: Assist device

Search Result 268, Processing Time 0.025 seconds

In Vivo Blood Compatibility of PU-PEO-SO3 as Coating Material for Blood Sac of Left Ventricular Assist Device ( LVAD) (좌심실보조장치의 혈액주머니용 코팅재료로서 PU-PEO-SO3의 in vivo 혈액적합성에 관한 연구)

  • 한동근;김종원
    • Journal of Biomedical Engineering Research
    • /
    • v.15 no.1
    • /
    • pp.19-26
    • /
    • 1994
  • Sulfonated poly (ethyleneoxide)-grafted polyurethane (PU-PEO-$SO_3$) prepared by bulk modification was coated on a blood sac for electrohydraulic left ventricular assist device (ELVAD) implanted in dogs and its in vivo blood compatibility on shear stress was studied as compared with untreated Po. The effect of the wall shear stress on the protein adsorption unlike platelet adhesion is dependent on the surface characteristics of the material, although less proteins seem to be adsorbed in the region of the high shear stress. The thickness of total proteins adsorbed on PU-PEO-SOJ (400 ${\AA}$) by trans¬mission electron microscopy(TEM) was considerably lower than that of untreated PU(l,000~1,600 ${\AA}$), but PU-PEO-$SO_3$ showed high albumin adsorption, low fibrinogen and IgG adsorption, and low platelet adhesion as compared with untreated PU, suggesting that PU-PEO-$SO_3$ is more in vivo blood compatible. Therefore, it appears that such a blood compatible PU-PEO-$SO_3$ is useful for blood contacting biomaterials including artificial organs.

  • PDF

Development of Pediatric VAD(VICT) and its in-vivo Test (소아용 좌심실 보조장치(VICT)의 개발 및 in-vivo 실험)

  • Lee, S.H.;Park, I.T.;Kim, S.H.;Lee, K.W.;Lee, K.H.;Ahn, H.
    • Proceedings of the KOSOMBE Conference
    • /
    • v.1996 no.05
    • /
    • pp.207-212
    • /
    • 1996
  • We developed pneumatic blood pump and its driving system as a pediatric ventricular assist device. The blood pump is diaphragm type system and its blood contacting area is coated with Bio-Span. The driving unit Is consists of dual pumps, valves for the reliable blood pumping and its controller uses 80C196(Intel) as a main processor. The acute animal experiment was performed with dogs and its body weight is about 20 kg. The maximum cardiac output is about 2.1 l/min and the pressure and flow curves showed reliable operation as assist device.

  • PDF

HeartMate 3 Implantation via Only Left Thoracotomy: A Case Report

  • Mi Young Jang;Jun Ho Lee;Su Ryeun Chung;Kiick Sung;Wook Sung Kim;Yang Hyun Cho
    • Journal of Chest Surgery
    • /
    • v.56 no.3
    • /
    • pp.224-227
    • /
    • 2023
  • Median sternotomy is a standard surgical technique used for left ventricular assist device (LVAD) implantation. However, if sternotomy has a prohibitive surgical risk, LVAD implantation can be performed through only left thoracotomy. We managed a patient with end-stage heart failure who had recently undergone coronary artery bypass grafting (CABG) elsewhere. The patient also had a deep sternal wound infection and bacteremia. Because of refractory cardiogenic shock, we performed extracorporeal membrane oxygenation (ECMO). After multiple mediastinal washouts and omental flap placement, ECMO was converted to extracorporeal LVAD (from the left ventricular apex to the descending aorta) through a left thoracotomy. The extracorporeal LVAD was maintained for 18 days and replaced by the HeartMate 3 LVAD. The patient was discharged in good condition 115 days after CABG.

Percutaneous OxyRVAD in a Patient with Severe Respiratory Failure and Right Heart Failure: A Case Report

  • Ga Young Yoo;June Lee;Seok Beom Hong;Do Yeon Kim
    • Journal of Chest Surgery
    • /
    • v.57 no.3
    • /
    • pp.319-322
    • /
    • 2024
  • Venovenous extracorporeal membrane oxygenation (VV ECMO) is often used in cases of severe respiratory failure, especially in patients considered for lung transplantation. However, because many lung diseases can ultimately result in right heart failure, the treatment of secondary right heart failure can present a challenge when the patient is already under VV ECMO support. In such cases, an oxygenated-right ventricular assist device (OxyRVAD) can be used. OxyRVAD is designed to maintain anterograde blood flow and prevent right ventricular distension. Moreover, the pulmonary arterial cannula can be inserted percutaneously. We report a case in which percutaneous OxyRVAD was successfully implemented to manage right heart failure in a patient with respiratory failure who was on VV ECMO.

EVALUATION OF LAGRANGIAN AND EULERIAN APPROACHES FOR PREDICTION OF HEMOLYSIS IN BLOOD PUMPS (혈액펌프내 혈액 변성 예측에 대한 Lagrangian 및 Eulerian 기법의 평가)

  • Hong, S.;Son, C.;Kang, S.;Hur, N.;Kim, W.;Kang, S.H.
    • Journal of computational fluids engineering
    • /
    • v.20 no.3
    • /
    • pp.79-86
    • /
    • 2015
  • A blood pump is an important part of a cardiac assist device. Since the shear rate in blood is known to be a primary factor on hemolysis generation, it has been very important to evaluate hemolysis inside blood pumps for understanding performance and reliability of cardiac assist devices. In this study, hemolysis generation inside blood pumps is analyzed using CFD with power-law based models for the blood damage index(BDI), in order to overcome difficulties in measuring hemolysis by experiment. The BDI values in blood pumps can be evaluated using Lagrangian or Eulerian approaches. In this study, several Lagrangian and Eulerian approaches are compared to estimate the efficiency of the numerical methods in a practice sense. It is found that the Eulerian approaches are advantageous in terms of the efficiency and robustness. Two different Eulerian approaches are used to evaluate the BDI values of a few commercial blood pumps. For the conditions of extracorporeal membrane oxygenator(ECMO) and ventricular assist device(VAD), local generation of hemolysis is analyzed using divided regions of blood pumps, in order to investigate the effects of the pump geometry.

Outcome of Extracorporeal Ventricular Assist Device for Cardiogenic Shock as a Bridge to Transplantation

  • Kim, Hyo-Hyun;Shin, Jung-Hoon;Kim, Jung-Hwan;Youn, Young-Nam
    • Journal of Chest Surgery
    • /
    • v.53 no.6
    • /
    • pp.368-374
    • /
    • 2020
  • Background: The extracorporeal ventricular assist device (e-VAD) system is designed for left ventricular support using a permanent life support console. This study aimed to determine the impact of temporary e-VAD implantation bridging on posttransplant outcomes. Methods: We reviewed the clinical records of 6 patients with the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1, awaiting heart transplantation, who were provided with temporary e-VAD from 2018 to 2019. The circuit comprised a single centrifugal pump without an oxygenator. The e-VAD inflow cannula was inserted into the apex of the left ventricle, and the outflow cannula was positioned in the ascending aorta. The median follow-up duration was 8.4±6.9 months. Results: After e-VAD implantation, lactate dehydrogenase levels significantly decreased, and Sequential Organ Failure Assessment scores significantly improved. Bedside rehabilitation was possible in 5 patients. After a mean e-VAD support duration of 14.5±17.3 days, all patients were successfully bridged to transplantation. After transplantation, 5 patients survived for at least 6 months. Conclusion: e-VAD may reverse end-organ dysfunction and improve outcomes in INTERMACS I heart transplant patients.

Modeling of Left Ventricular Assist Device and Suction Detection Using Fuzzy Subtractive Clustering Method (퍼지 subtractive 클러스터링 기법을 이용한 좌심실보조장치 모델링 및 흡입현상 검출)

  • Park, Seung-Kyu;Choi, Seong-Jin
    • Journal of the Korean Institute of Intelligent Systems
    • /
    • v.22 no.4
    • /
    • pp.500-506
    • /
    • 2012
  • A method to model left ventricular assist device (LVAD) and detect suction occurrence for safe LVAD operation is presented. An axial flow blood pump as a LVAD has been used to assist patient with heart problems. While an axial flow blood pump, a kind of a non-pulsatile pump, has relative advantages of small size and efficiency compared to pulsatile devices, it has a difficulty in determining a safe pump operating condition. It can show different pump operating statuses such as a normal status and a suction status whether suction occurs in left ventricle or not. A fuzzy subtractive clustering method is used to determine a model of the axial flow blood pump with this pump operating characteristic and the developed pump model can provide blood flow estimates before and after suction occurrence in left ventricle. Also, a fuzzy subtractive clustering method is utilized to develop a suction detection model which can identify whether suction occurs in left ventricle or not.

Development of FSR Sensor Suits Controlling Walking Assist System for Paraplegic Patients (하반신 마비환자의 보행보조시스템 제어를 위한 저항 센서 슈트 개발)

  • Jang, E.H.;Chi, S.Y.;Lee, J.Y.;Cho, Y.J.;Chun, B.T.
    • Journal of Biomedical Engineering Research
    • /
    • v.31 no.4
    • /
    • pp.269-274
    • /
    • 2010
  • The purpose of this study was to develop the FSR sensor suit that controls walking assist device for paraplegic patients. The FSR sensor suit was to detect user's intent and patterns for walking by measuring pressure on the palm and the sole of user's foot. It consisted of four modules: sensing pressure from palm, changing modes and detecting pressure on the palm/at the wrist, sensing pressure from the soles of user's foot, and host module that transmit FSR data obtained from sensing modules to PC. Sensing modules were connected to sensing pads which detect analog signals obtained from the palm or the sole of foot. These collect signals from the target regions, convert analog signals into digital signals, and transmit the final signals to host module via zigbee modules. Finally, host modules transmit the signals to host PC via zigbee modules. The study findings showed that forces measured at the palm when using a stick reflected user's intent to walk and forces at the sole of the user's foot revealed signals detecting walking state.

Animal Experiment and Blood Biocompatibility Study of Polymer Valve (고분자판막의 동물실험 및 생체내 혈액적합성 연구)

  • 김상현;홍유선
    • Journal of Chest Surgery
    • /
    • v.30 no.4
    • /
    • pp.357-362
    • /
    • 1997
  • In vivo testings of the monoleaflet polymer valve were performed in seven dogs to prove its blood biocompatibility. The monoleaflet polymer valve used in this study was developed for short-term usage n the ventricular assist device. The frame and leaflet of the polymer valve were made of polyurethane. The inter-aortic valved conduit were implanted in four dogs and the ventriculo-atrial valved conduit was implanted in one dog. The ventricular assist devices with polymer valve were implanted in two dogs. The longest survival was 20 days. Main causes of death were bleeding and infection. To examine the blood compatibility, each blood sample was collected and RBC, WBC, hematocrit, hemoglobin, platelet and lactic acid dehydrogenase were analyzed. These studies thus far demonstrated that, with further development, a reliable and inexpensive polymer valve will be used in the ventricular assist device as short term usage.

  • PDF

A Case Report of Heart Transplantation Bridged by Bi-ventricular Assist Device in a Pediatric Patient of Prerenal Type ARF (소아환자에서 양심실 순환보조를 중개로 한 후 발생한 급성신부전 환자에서의 심장 이식수술 치험 1예)

  • Ra, Yong-Joon;Koak, Jae-Gun;Kim, Jin-Hyun;Oh, Se-Jin;Lee, Jae-Hang;Kim, Woong-Han
    • Journal of Chest Surgery
    • /
    • v.39 no.11 s.268
    • /
    • pp.854-857
    • /
    • 2006
  • The patient was an eight-year-old female. She was diagnosed as dilated cardiomyopathy. She was supported with bi-ventricular assist because of heart failure for 15 days. After 7 days, she was suffered from prerenal type ARF and support with continuous veno-veno hemodyalisis(CVVHD). And then heart transplantation was performed, heart donor's blood type was A. Immune suppressants were used after due consideration for renal toxicity. ARF was resolved on post operative $14^{th}$ day. She was discharged on post operative $52^{nd}$ day without any specific post operative complication. She has been followed up without any immune rejection reaction upto 14 months.